Dr Schuell and colleagues investigated whether a relationship between chemotherapy-associated adverse events and treatment efficacy exists.
The research team have analyzed the toxicity, objective response and survival data of 303 patients with advanced colorectal cancer.
Patients were divided into 2 groups, including the 245 with beneficial effect in Group 1, and 58 in Group 2 with progressive disease.
The team analyzed differences in terms of incidence rates, type and severity of adverse events, using univariate and multivariate models.
|There was an inverse correlation between disease control and treatment tolerance|
|British Journal of Cancer|
The median number of side effects in Group 1 was 6 vs 4 in Group 2.
The researchers found an inverse correlation between disease control and treatment tolerance.
The team confirmed this correlation when side effects were analyzed according to severity and type of treatment-associated toxicities.
When median survival was analyzed according to the number of adverse events, it was 10, 16, and 18 months in case of 0 to1, 2 to 5, and 6 adverse events, respectively.
Dr Schuell's team concludes, “The results of this analysis suggest that occurrence of side effects during chemotherapy in advanced colorectal cancer is an independent and reliable prognostic indicator for response and survival.”